Case Report
Copyright ©The Author(s) 2020.
World J Clin Oncol. Nov 24, 2020; 11(11): 959-967
Published online Nov 24, 2020. doi: 10.5306/wjco.v11.i11.959
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Initial computed tomography images of abdomen and pelvis displaying two hypoattenuating liver masses, which are most consistent with liver metastases from invasive colorectal carcinoma. Images were captured on 7/25/2016.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Trend in carcinoembryonic antigen levels during irinotecan with oxaliplatin rechallenge therapy. CEA: Carcinoembryonic antigen; IROX: Irinotecan with oxaliplatin.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Computed tomography abdomen images showed interval response with decrease in liver metastasis size. These images show size of the metastatic lesion at 4- and 5-mo post initiation of irinotecan with oxaliplatin rechallenge therapy. CT: Computed tomography.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Timeline summary of events. CT: Computed tomography; FOLFOX: Folinic acid, 5-fluorouracil, and oxaliplatin; CEA: Carcinoembryonic antigen; IROX: Irinotecan and oxaliplatin; KRAS: Kirsten rat sarcoma viral oncogene; BRAF: B-Raf oncogene.